UB Paderborn / Katalog / Suche / in CDI

Autopsy among recipients of stem cell transplant for hematologic malignancies in the modern era

Bone marrow transplantation (Basingstoke), 2021-01, Vol.56 (1), p.282-284

2021

Link zum Volltext

Verfügbarkeit prüfen

Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma

Haematologica (Roma), 2017-07, Vol.102 (7), p.e261

2017

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

Blood cancer journal (New York), 2024-04, Vol.14 (1), p.69-69, Article 69

2024

Link zum Volltext

Verfügbarkeit prüfen

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD‐MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL

HemaSphere, 2023-08, Vol.7 (S3), p.e1332195-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation

EJHaem, 2023-08, Vol.4 (3), p.775-778

2023

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2901-2912

2022

Link zum Volltext

Verfügbarkeit prüfen

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

The New England journal of medicine, 2022-07, Vol.387 (2), p.132-147

2022

Link zum Volltext

Verfügbarkeit prüfen

Coexisting sporadic late onset nemaline myopathy and AL amyloid myopathy – incidental or related?

Neuromuscular disorders : NMD, 2022-06, Vol.32 (6), p.533-538

2022

Link zum Volltext

Verfügbarkeit prüfen

Survival Of Patients With Monoclonal Gammopathy Of Undetermined Significance And Transthyretin Amyloid Cardiomyopathy

Journal of cardiac failure, 2024-01, Vol.30 (1), p.132-133

2024

Link zum Volltext

Verfügbarkeit prüfen

HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.10-10

2020

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis of paraproteinemic neuropathy: Room for improvement

Journal of the neurological sciences, 2020-08, Vol.415, p.116902-116902, Article 116902

2020

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

Clinical lymphoma, myeloma and leukemia, 2020-08, Vol.20 (8), p.509-518

2020

Link zum Volltext

Verfügbarkeit prüfen

An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.1654-1654

2021

Link zum Volltext

Verfügbarkeit prüfen

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7261-7263

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.7275-7277

2022

Link zum Volltext

Verfügbarkeit prüfen

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Blood, 2022-11, Vol.140 (Supplement 1), p.10077-10078

2022

Link zum Volltext

Verfügbarkeit prüfen

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Blood, 2022-11, Vol.140 (Supplement 1), p.7284-7285

2022

Link zum Volltext

Verfügbarkeit prüfen

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

Blood, 2020-11, Vol.136 (Supplement 1), p.8-9

2020

Link zum Volltext

Verfügbarkeit prüfen

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.483-483

2021

Link zum Volltext

Verfügbarkeit prüfen

Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience

Clinical lymphoma, myeloma and leukemia, 2022-02, Vol.22 (2), p.105-112

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Autopsy among recipients of stem cell transplant for hematologic malignancies in the modern era

Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD‐MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL

Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Coexisting sporadic late onset nemaline myopathy and AL amyloid myopathy – incidental or related?

Survival Of Patients With Monoclonal Gammopathy Of Undetermined Significance And Transthyretin Amyloid Cardiomyopathy

HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Diagnosis of paraproteinemic neuropathy: Room for improvement

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience

Suchergebnisse filtern